Lanabecestat

Drug Profile

Lanabecestat

Alternative Names: AZD3293; BACE inhibitor - AstraZeneca; Beta secretase inhibitor - AstraZeneca; LY 3314814

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astex Pharmaceuticals; AstraZeneca
  • Developer AstraZeneca; Eli Lilly
  • Class Antidementias; Imidazoles; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 24 Jul 2017 Eli Lilly plans a phase I trial in Healthy volunteers in United Kingdom (NCT03222427)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory applications for Alzheimer's disease in USA, European Union and Japan in 2020 (AstraZeneca pipeline, July 2017)
  • 22 May 2017 Eli Lilly and AstraZeneca completes a phase I drug-interaction trial in Healthy volunteers in USA (PO) (NCT03019549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top